time to relapse
Figure 2 · Panel Pediatric_population
Panel Pediatric_population 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Donald L Gilbert, Sarah D Atkinson, David J B Kim, Meredith M Miller, Patricia M Rice, John A Flatt, George B Karkanias, Frederick E Munschauer, Richard M Bittman, Stephen P Wanaski, Timothy M Cunniff, Kinga K Tomczak
JAMA Neurol 83(7) 645-653
IMPORTANCE: Current Tourette syndrome (TS) pharmacotherapy is hindered by adverse effects and high discontinuation rates. OBJECTIVE: To evaluate the safety and maintenance of effect of ecopipam, a selective dopamine D1 receptor antagonist, for up to 24 weeks for TS. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was a phase 3, double-blind, placebo-controlled, randomized withdrawal study conducted between January 31, 2023, and February 4, 2025. Participants were enrolled at 77 sites in 12 countries. Individuals 6 years and older with TS were eligible. INTERVENTION: In the 12-week, open-label period, ecopipam was titrated over 3 to 4 weeks (target dose, 1.8 mg/kg per day). Responders (≥25% improvement in Yale Global Tic Severity Scale Total Tic Score [YGTSS-TTS] at weeks 8 and 12) were randomized to continue ecopipam or taper to placebo for the 12-week double-blind period. MAIN OUTCOMES AND MEASURES: Time to relapse (≥50% loss of open-label period YGTSS-TTS improvement) in participants aged 6 to 18 years (primary) and adults (exploratory). RESULTS: The trial enrolled 216 participants (n = 167 [77.3%] pediatric; 146 [67.6%] male and 70 [32.4%] female) to the open-label ecopipam period. Of these, 43 pediatric participants (mean [SD] age, 14.3 [5.5] years) and 8 adult participants were randomized to receive ecopipam; 47 pediatric (mean [SD] age, 14.0 [5.8] years) and 6 adult participants were randomized to receive placebo. Ecopipam significantly reduced the relapse risk vs placebo in pediatric participants (hazard ratio [HR], 0.47; 95% CI, 0.26-0.84; P = .008; n = 90). In adults, the effect was directionally similar (HR, 0.51; 95% CI, 0.11-2.30; P = .37; n = 14) but not significant. The most frequently reported adverse events with ecopipam (open-label and double-blind periods) were somnolence (n = 24 [11.1%]), anxiety (n = 21 [9.7%]), headache (n = 21 [9.7%]), insomnia (n = 19 [8.8%]), tic (n = 17 [7.9%]), and fatigue (n = 14 [6.5%]). Ecopipam did not have a clinically meaningful impact on weight, metabolic parameters, or psychiatric scale measures. Drug-induced movement disorders were not observed. CONCLUSIONS AND RELEVANCE: Ecopipam maintained clinically meaningful TS symptom improvements and was well tolerated for up to 24 weeks. Adverse events primarily affected the central nervous system. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05615220.
1 个 Figure · 2 个 KM 面板
Figure 2.. Kaplan-Meier Curves for Time to Relapse in the Pediatric Population (A) and Overall Population (B) From Randomization (Week 12) The plus (+) sign indicates censored data. Relapse was defined as ≥50% loss of improvement in Yale Global Tic Severity Scale Total Tic Score previously observed from baseline to week 12, initiation of additional medications for Tourette syndrome symptoms, or hospitalization related to worsening symptoms. HR indicates hazard ratio.
Figure 2 · Panel Pediatric_population
Panel Pediatric_population 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel Overall_population
Panel Overall_population 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。